These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
54. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695 [TBL] [Abstract][Full Text] [Related]
55. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease. Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911 [TBL] [Abstract][Full Text] [Related]
56. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure. Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144 [TBL] [Abstract][Full Text] [Related]
57. Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure. Hori M Future Cardiol; 2013 Mar; 9(2):163-76. PubMed ID: 23463968 [TBL] [Abstract][Full Text] [Related]